Evidence map›Paper›PMID 38568967›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2024

SARS-CoV-2 nsp15 endoribonuclease antagonizes dsRNA-induced antiviral signaling.

Clayton J Otter, Nicole Bracci, Nicholas A Parenti, Chengjin Ye, Abhishek Asthana, Ebba K Blomqvist, Li Hui Tan, Jessica J Pfannenstiel, Nathaniel Jackson, Anthony R Fehr and 5 more

Open access · hybridAbstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.

0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed
15.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

42 citing papers in PubMed, 42 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. SARS-CoV-2 and MERS-CoV disrupt host protein synthesis via nsp1 with differential effects on the integrated stress response.Proceedings of the National Academy of Sciences of the United States of America · 2026
    Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. SARS-CoV-2 nsp15 enhances viral virulence by subverting host antiviral defenses.Proceedings of the National Academy of Sciences of the United States of America · 2025
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

15 authors at 6 institutions in 1 country.

Clayton J Otter *Department of Microbiology, University of Pennsylvania, Philadelphia, PA 19104.ORCID 0000-0003-1609-8105
Nicole Bracci *Department of Microbiology, University of Pennsylvania, Philadelphia, PA 19104.
Nicholas A Parenti *Department of Microbiology, University of Pennsylvania, Philadelphia, PA 19104.ORCID 0000-0003-3673-1027
Chengjin YeDisease Intervention and Prevention, Texas Biomedical Research Institute, San Antonio, TX 78227.ORCID 0000-0002-1934-9494
Abhishek AsthanaDepartment of Cancer Biology, Lerner Research Institute, Cleveland Clinic, Cleveland, OH 44195.
Ebba K BlomqvistDepartment of Molecular Medicine, The Herbert Wertheim University of Florida Scripps Institute for Biomedical Innovation & Technology, Jupiter, FL 33458.
Li Hui TanDepartment of Otorhinolaryngology-Head and Neck Surgery, University of Pennsylvania, Philadelphia, PA 19104.
Jessica J PfannenstielDepartment of Molecular Biosciences, University of Kansas, Lawrence, KS 66045.
Nathaniel JacksonDisease Intervention and Prevention, Texas Biomedical Research Institute, San Antonio, TX 78227.
Anthony R FehrDepartment of Molecular Biosciences, University of Kansas, Lawrence, KS 66045.ORCID 0000-0003-1560-1573
Robert H SilvermanDepartment of Cancer Biology, Lerner Research Institute, Cleveland Clinic, Cleveland, OH 44195.ORCID 0000-0003-2432-992X
James M BurkeDepartment of Molecular Medicine, The Herbert Wertheim University of Florida Scripps Institute for Biomedical Innovation & Technology, Jupiter, FL 33458.ORCID 0000-0002-5525-3641
Noam A CohenDepartment of Otorhinolaryngology-Head and Neck Surgery, University of Pennsylvania, Philadelphia, PA 19104.
Luis Martinez-SobridoDisease Intervention and Prevention, Texas Biomedical Research Institute, San Antonio, TX 78227.ORCID 0000-0001-7084-0804
Susan R WeissDepartment of Microbiology, University of Pennsylvania, Philadelphia, PA 19104.ORCID 0000-0002-8155-4528
University of Pennsylvania · USTexas Biomedical Research Institute · USCleveland Clinic Lerner College of Medicine · USPhiladelphia VA Medical Center · USUniversity of Florida · USUniversity of Kansas · US

Funding

Synthetic Chemical Biology CoreP20GM113117 · NIGMS · UNIVERSITY OF KANSAS LAWRENCE · PI HEFTY, P SCOTT · 2016 to 2025
$23.9M
University of Pennsylvania Postdoctoral Opportunities in Research and TeachingK12GM081259 · NIGMS · UNIVERSITY OF PENNSYLVANIA · PI Janis K. Burkhardt · 2007 to 2026
$20.1M
Control of Viral Pathogenesis by Regulation of 2-5A LevelsR01AI104887 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI SILVERMAN, ROBERT H., WEISS, SUSAN R · 2013 to 2023
$7.6M
TRAINING IN VIROLOGYT32AI007324 · NIAID · WISTAR INSTITUTE · PI Paul Bates, Matthew D. Weitzman · 1989 to 2026
$6.8M
MERS coronavirus: antagonism of double-stranded RNA induced host response by accessory proteinsR01AI140442 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI Susan R Weiss · 2018 to 2026
$5.1M
Training in Emerging Infectious DiseasesT32AI055400 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI CHERRY, SARA, HENSLEY, SCOTT ERIC · 2003 to 2022
$4.4M
Human coronavirus infection of the nasal epitheliumR01AI169537 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI Noam A Cohen, Susan R Weiss · 2022 to 2026
$3.7M
Determining mechanisms of innate immune modulation by ADP-ribosylationR35GM138029 · NIGMS · UNIVERSITY OF KANSAS LAWRENCE · PI Anthony R Fehr · 2020 to 2026
$2.7M
The origin and future protective activity of SARS-CoV-2 RBD specific neutralizing antibodiesR01AI161175 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI KOBIE, JAMES J, MARTINEZ-SOBRIDO, LUIS · 2021 to 2024
$2.5M
Understanding the OAS/RNase L pathway during pathogenic viral infectionsR35GM151249 · NIGMS · UNIVERSITY OF FLORIDA · PI James M Burke · 2023 to 2026
$1.9M
Antiviral innate immune responses to pathogenic coronaviruses in the nasal epitheliumF30AI172101 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI OTTER, CLAYTON · 2023 to 2024
$68k
COVID-19: Elucidating the Role of the NasalEpithelium in SARS-CoV-2 Infection, Transmission, and PreventionI01BX005432 · VA · PHILADELPHIA VA MEDICAL CENTER · PI COHEN, NOAM A · 2021 to 2023
–
BLRD VA I01 BX005432NIAID NIH HHS F30 AI172101NIAID NIH HHS R01 AI104887NIAID NIH HHS R01 AI140442NIAID NIH HHS R01 AI161175NIAID NIH HHS R01 AI169537NIAID NIH HHS T32 AI007324NIAID NIH HHS T32 AI055400NIGMS NIH HHS K12 GM081259NIGMS NIH HHS P20 GM113117NIGMS NIH HHS R35 GM138029NIGMS NIH HHS R35 GM151249
6 · The paper itself

Abstract

Severe acute respiratory syndrome coronavirus (SARS-CoV)-2 has caused millions of deaths since its emergence in 2019. Innate immune antagonism by lethal CoVs such as SARS-CoV-2 is crucial for optimal replication and pathogenesis. The conserved nonstructural protein 15 (nsp15) endoribonuclease (EndoU) limits activation of double-stranded (ds)RNA-induced pathways, including interferon (IFN) signaling, protein kinase R (PKR), and oligoadenylate synthetase/ribonuclease L (OAS/RNase L) during diverse CoV infections including murine coronavirus and Middle East respiratory syndrome (MERS)-CoV. To determine how nsp15 functions during SARS-CoV-2 infection, we constructed a recombinant SARS-CoV-2 (nsp15

Indexed as

COVID-19SARS-CoV-2AnimalsAntiviral AgentsEndoribonucleasesMiceSignal TransductionAntiviral AgentsEndoribonucleasesdsRNA-induced pathwaysendoribonucleaseinterferonnsp15SARS-CoV-2

Identifiers

PMID38568967
PMCPMC11009620
OpenAlexW4393864529

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.